Indication
Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
Loading your page…
Loading your page…
Hemolysis;Anemia, Hemolytic, Autoimmune
Marketing Authorisation Holder: Recordati Rare Diseases
EMA Authorisation: 15/11/2022
INN: sutimlimab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Enjaymo: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.